Attorney Docket: P50770X1C1

IN THE CLAIMS:

Cancel claims 1-39, without prejudice or disclaimer.

Please add the following claims:

40. An antibody comprising six complementarity determining regions (CDRs) from an antigen specific donor antibody of a rodent and acceptor framework comprising amino acid residues from an Old World Ape.

41. The antibody of claim 40, wherein the rodent is mouse.

42. The antibody of claim 40, wherein the rodent is rat.

43. The antibody of claim 40, wherein the Old World Ape is *Pan troglodytes, Pan paniscus* or *Gorilla gorilla.*

44. The antibody of claim 40, wherein the Old World Ape is *Pan troglodytes.*

45. The antibody of claim 40, wherein at least one acceptor framework amino acid residue is replaced with corresponding residues from the donor framework.

46. The antibody of claim 40, wherein at least one acceptor framework amino acid residue that influences CDR presentation is replaced with corresponding residues from the donor framework.

46. The antibody of claim 40, wherein the acceptor framework comprises an analog of an amino acid residues from an Old World Ape.

47. The antibody of claim 40, wherein the acceptor framework comprises a light (VL) and heavy (VH) chain region each comprising four acceptor framework regions (framework I, II, III, and IV), and wherein the VH acceptor framework I, II, III and IV are from chimpanzee.

48. The antibody of claim 47, wherein the VH acceptor framework I, II and III comprise an amino acid sequence as set forth in SEQ ID NOs: 10, 11, 12, 13, 14, 15, 16, 17 or 18.

49. The antibody of claim 47, wherein the VH acceptor framework IV comprises an amino acid sequence as set forth in SEQ ID NOs: 81, 82, 83, 84 or 85.

50. The antibody of claim 40, wherein VL comprises segments Vκ and Vλ, and wherein Vκ comprises four acceptor framework regions (framework I, II, III, and IV), and wherein Vκ acceptor framework I, II, III and IV are from chimpanzee.

51. The antibody of claim 50, wherein Vκ acceptor framework I, II, and III comprise an amino acid sequence as set forth in SEQ ID NOs: 28, 29, 30, 31, 32, 33, 34, 35 or 36.

52. The antibody of claim 50, wherein Vκ acceptor framework IV comprises an amino acid sequence as set forth in SEQ ID NOs: 86 or 87.

53. The antibody of claim 40, wherein the acceptor framework comprises a light (VL) and heavy (VH) chain region each comprising four framework regions (framework I, II, III, and IV), and wherein the VH acceptor framework I, II, III and IV are from *cynomolgus*.

54. The antibody of claim 53, wherein the VH acceptor framework I, II and III comprise an amino acid sequence as set forth in SEQ ID NOs: 45, 46, 47, 48, 49, 50, 51 or 52.

55. The antibody of claim 53, wherein the VH acceptor IV comprises an amino acid sequence as set forth in SEQ ID NOs: 88, 89, 90, 91, 92 or 93.

56. The antibody of claim 53, wherein the VL comprises segments Vκ and Vλ, and wherein Vκ comprises four acceptor framework regions (framework I, II, III, and IV), and wherein Vκ acceptor framework I, II, III and IV are from *cynomolgus*.

57. The antibody of claim 56, wherein Vκ acceptor framework I, II and III comprise an amino acid sequence as set forth in SEQ ID NOs: 59,-60, 61, 62, 63 or 64.

58. The antibody of claim 56, wherein the Vκ acceptor framework IV comprises an amino acid sequence as set forth in SEQ ID NOs: 94, 95 or 96.

59. The antibody of claim 40, wherein the amino acid sequence of the complete light chain is set forth in SEQ ID NO: 68 and the amino acid sequences of the heavy chain is set forth in SEQ ID NO: 70.

60. The antibody of claim 40, wherein the amino acid sequence of the complete light chain is set forth in SEQ ID NO: 73 and the amino acid sequences of the heavy chain is set forth in SEQ ID NO: 74.

61. The antibody of claim 40, wherein the amino acid sequence of the complete light chain is set forth in SEQ ID NO: 77 and the amino acid sequences of the heavy chain is set forth in SEQ ID NO: 78.

62. An antigen specific antibody of a rodent wherein one or more framework amino acid residues that do not influence CDR presentation are replaced with corresponding residues from Old World Ape.

63. A method for making an antibody having reduced immunogenicity in humans comprising grafting all six CDRs from antigen-specific rodent antibodies onto homologous Old World Ape acceptor frameworks.

GROUP III IN RESTRICTION

REMARKS

Claims 1, 3-4, 6, and 32-39 are pending in this application. Claims 1, 3-4 and 6, 32-35 and 39 stand rejected. Claims 36-38 are objected to. Applicant has herein cancelled all pending claims, has added new claims that are supported by the specification, and has